Acute management of unstable angina and non-ST segment elevation myocardial infarction
Fernando Morita Fernandes Silva1, Antonio Eduardo Pereira Pesaro1, Marcelo Franken1
1Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Insights
Non-ST segment elevation coronary syndrome, often caused by plaque instability, requires treatments to reduce pain and damage. Despite new antiplatelet and anticoagulation drugs, high rates of mortality and infarction persist.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Pharmacology
Background:
- Non-ST segment elevation coronary syndrome (NSTE-ACS) typically arises from atherosclerotic plaque rupture.
- This event triggers platelet aggregation and coagulation cascade activation, leading to myocardial ischemia.
- Current treatment goals include alleviating ischemic pain, minimizing heart muscle damage, and reducing mortality.
Purpose of the Study:
- To review the current therapeutic strategies for NSTE-ACS.
- To evaluate the efficacy and safety of existing and novel antiplatelet and anticoagulation agents.
- To address the persistent high rates of mortality, infarction, and hospital readmission in NSTE-ACS patients.
Main Methods:
- Review of pharmacological agents used in managing NSTE-ACS.
- Analysis of clinical trial data on antiplatelet and anticoagulation therapies.
- Examination of treatment outcomes, including ischemic events and bleeding complications.
Main Results:
- Established antiplatelet and anticoagulation agents are cornerstones of NSTE-ACS management.
- Newer drugs offer potential for improved anti-ischemic efficacy and reduced bleeding risk.
- Despite therapeutic advancements, significant residual risks for mortality, myocardial infarction, and readmission remain.
Conclusions:
- The management of NSTE-ACS has evolved with new pharmacological options.
- Further research is needed to optimize treatment strategies and mitigate persistent adverse outcomes.
- Balancing anti-ischemic benefits against bleeding risks remains a critical challenge in NSTE-ACS therapy.
Abstract:
Non-ST segment elevation coronary syndrome usually results from instability of an atherosclerotic plaque, with subsequent activation of platelets and several coagulation factors. Its treatment aims to reduce the ischemic pain, limiting myocardial damage and decreasing mortality. Several antiplatelet and anticoagulation agents have been proven useful, and new drugs have been added to the therapeutic armamentarium in the search for higher anti-ischemic efficacy and lower bleeding rates. Despite the advances, the mortality, infarction and readmission rates remain high.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:20Angina V: Nursing Management
01:30Acute Coronary Syndrome I: Introduction
01:26Acute Coronary Syndrome V: Nursing Management
01:27Angina II: Classification